Date: 2014-07-16
Type of information: Series D financing round
Company: Immatics (Germany)
Investors: dievini Hopp Biotech (Germany), Wellington Partners (USA), MIG-advised funds, AT Impf GmbH (Germany)
Amount: €34 million
Funding type: Series D financing round
Planned used: immatics will use this funding to complete the current phase 3 trial with its lead cancer vaccine IMA901 in patients with renal cell carcinoma (RCC). The trial is evaluating overall survival with IMA901 in combination with sunitinib (Sutent®, Pfizer), a current standard first-line therapy, compared with sunitinib alone in patients with metastatic and/ or locally advanced RCC. Final data from the study are expected in 2015. The fundraising will also allow immatics to invest in its unique XPRESIDENT® platform to extend its “Human Immunopeptidome Program” which is focused on identifying novel, high quality targets for the most common cancer indications. As part of this program, immatics will also use XPRESIDENT® to screen the immunopeptidome of relevant healthy tissue to ensure the selectivity of its novel targets based on their exclusive or strong over-presentation in tumors vs. healthy tissues.
Others: * On July 16, 2014, immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, announced that it has received €22m to complete a Series D financing round. The Company received €12m in October 2013 as an initial tranche of the total €34m funding round. * On October 15, 2013, immatics biotechnologies, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines, has announced that it has closed a €34 million Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive the first €12 million tranche of funding immediately. The new funds will enable immatics to conclude the development of its lead cancer vaccine IMA901, including completing all of the activities necessary to prepare for regulatory filings in the US and Europe. IMA901 is in a pivotal phase 3 trial. The trial has completed inclusion of 339 patients at sites in the US and Europe. Interim overall survival results are expected in 2014, with final data in 2015. The phase 3 trial builds on the positive phase 2 study with IMA901 in advanced renal cell carcinoma patients. The trial showed that patients who produced an immune response to two or more of the TUMAPs contained in IMA901 had a significantly longer survival, as published in Nature Medicine in 2012. It has orphan drug designation in the US and Europe for the treatment of renal cell carcinoma in HLA-A*02 positive patients.
Therapeutic area: Cancer - Oncology
